We accelerate access to affordable and innovative medicines because Good Health Can’t Wait.
Promises
Principles
Empathy
We understand the needs of our patients
and partners better than others.
Dynamism
We solve challenges that only a few
can, and do this with agility.
Values
In pursuit of providing affordable and innovative medicines for healthier lives, we will create an environment of innovation and learning while continuously reaching for higher levels of excellence
INTEGRITY AND TRANSPARENCY
We will uphold the highest standards of integrity and transparency in all our transactions.
SAFETY
We are committed to providing safe working environments through continuous improvements in our infrastructure, work practices and behaviours.
QUALITY
We are dedicated to designing quality into our products and processes to delight our stakeholders.
PRODUCTIVITY
We strive to achieve more with less through a culture of innovation, continuous improvement and sustained focus on elimination of waste.
RESPECT FOR THE INDIVIDUAL
We are committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals.
COLLABORATION AND TEAMWORK
We will leverage expertise and resources from across our global network to create greater value for our stakeholders.
SUSTAINABILITY
We will create value for our stakeholders in a manner that respects our natural environment and serves the best interests of the communities in which we live and work.
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
2
3
4
5
6
7
8
9
0
1985
Our first API factory in Bollaram, Hyderabad, commenced operation.
1986
We went public and were listed on the Bombay Stock Exchange. We launched APIs for the first time in India. In the 1980s, we were among the earliest Indian pharma companies to export APIs to USA at scale.
1991
Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.
1992
We expanded our operations internationally by opening a branch in Russia.
1993
We were among earliest in Indian pharma to initiate new drug discovery through the Dr. Reddy’s Research Foundation.
1996
Dr. Anji Reddy founded the Dr. Reddy’s Foundation (DRF) to give back to society. Today, our company’s CSR activities include work in health, education, livelihood and environmental sustainability.
1997
We were the first Indian pharma company to out-license a novel drug to an innovator.
2001
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first Indian pharma company to obtain a 180-day marketing exclusivity from the USFDA (Fluoxetine capsules 40mg).
Our founder, Dr. Anji Reddy, received the Padma Shri from the Gov’t of India.
We pioneered the concept of 'Self-Managed Teams' to provide skilling and livelihood opportunities to youths around our plant sites.
2002
Aurigene Discovery Technologies Ltd (today, Aurigene Oncology Ltd), our subsidiary in Bengaluru, was incorporated for new drug discovery.
2003
We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.
2006
We became the fastest Indian pharma company to cross USD 1 billion in revenue.
We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (nasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).
2007
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
2010
We launched the world’s then first and India’s only generic of darbepoetin alfa (Cresp) in India.
We adopted 6 sustainability goals for the next decade.
2011
Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Gov’t of India for his contribution to the Indian pharma industry.
2016
We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.
2019
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.
We entered the nutraceuticals segment in India with the launch of our diabetes nutrition product, Celevida.
We became the first foreign generics company to receive approval to supply an existing product (Olanzapine) to China's public hospitals under the QCE system.
2020
We became the first company in India and third in Asia to join the Science-Based targets initiative (SBTi).
We acquired select divisions of Wockhardt in India.
We completed #40YearsOfDrReddys on 24th February, 2024.
2020-2021
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate and severe COVID-19.
Our focus on agility, access and affordability helped us reach over 5 million patients during the pandemic, especially in low and middle income countries.
2022
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
Our biggest manufacturing facility in Hyderabad was recognised by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
We refreshed our ESG goals to make them bold, measurable, accountable and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech. We acquired medical cannabis company, Nimbus Health GmbH, in Germany.
2023
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
Our platform ‘Celevida Wellness’ became our first D2C e-commerce platform in India carrying our products for diabetes nutrition and third-party brands.
Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
